Evaluating potential liver damage in an additional clinical trial would be needed for approval of Motif Bio's antibiotic iclaprim, which received a complete response letter in February. The path forward become clearer after the firm met with US regulators last month.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
